Zhejiang Huakang Pharmaceutical Co (605077) Fair Value & Analysis
Basic Materials · CN · Market cap 3.7B CNY
Fair value as of: Jul 12, 2026
From 16 valuation models · updated 29 days ago
Share price +4.8% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from ¥8.43 (bear) to ¥14.05 (bull), base ¥11.24. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 45/100 (below-average quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range ¥10.04 – ¥40.45 · fair‑value band ¥8.43 – ¥14.05 · the ¥11.06 price screens below the ¥11.24 fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Zhejiang Huakang Pharmaceutical Co (605077) currently trades at ¥11.06, while our model-based Fair Value estimate is ¥11.24, implying the stock looks roughly 1.6% fairly valued today. The Quality Score stands at 45/100 (below-average quality), in the Basic Materials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Zhejiang Huakang Pharmaceutical Co generated revenue of 4.6B CNY at a net margin of 3.1%. Revenue grew 45.3% year over year. It earns a return on equity of 4.3%. Net debt stands at 1.7B CNY. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥8.43 (bear case) to ¥14.05 (bull case); at ¥11.06, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 45% below its 52-week high, currently below its 200-day average. For context, the median of 10 Basic Materials peers we cover trades at -46% fair-value upside, at 2%, 605077 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Growth Earnings (¥19.02) versus Economic Profit (¥6.97). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 46 · Market factors (momentum, volatility) 25
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Zhejiang Huakang Pharmaceutical Co., Ltd. engages in the research, production, and sale of polyols and starch sugar worldwide.
Full company description
Zhejiang Huakang Pharmaceutical Co., Ltd. engages in the research, production, and sale of polyols and starch sugar worldwide. It offers polyols products such as xylitol, is a polyol that occurs naturally regular sugar raise blood sugar levels; sorbitol, is produced by the catalytic hydrogenation of D-glucose and is available as a free-flowing crystalline powder, and as aqueous solutions; maltitol a bulk sweetener produced from naturally occurring compounds in corn; erythritol, is produced by the enzymatic hydrolysis of starch into glucose, non-caloric, non-hygroscopic excipient with excellent sweet taste and cooling effect; lactitol is produced by hydrogenation of lactose; mannitol is derived from enzymatic hydrolysis of starch; isomalt is produced from sucrose as a raw material and transformed into isomaltulose by sucrose isomerase. In addition, the company offers starch sugar provide high fructose, glucose, maltose syrups, maltodextrin; as well as rare sugar d- xylose, and l-arabinose; and dietary fiber include polydextrose. Zhejiang Huakang Pharmaceutical Co., Ltd. was founded in 2001 and is based in Quzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zhejiang Huakang Pharmaceutical Co reported revenue of ¥4.2B in FY2025 versus ¥1.6B in FY2021, a compound +27.3%/yr. Reported net income was ¥200M in FY2025, compounding −4.1%/yr from FY2021.
Watch 605077: get an alert when its fair value changes →
Peer Group
Chemicals · 334 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Chemicals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Chemicals stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| BASF SE BASN | 1,034 MXN | 532.13 MXN | -49% |
| Ningxia Baofeng Energy Group 600989 | ¥20.32 | ¥20.17 | -1% |
| Zhejiang Juhua Co 600160 | ¥42.85 | ¥23.35 | -46% |
| PT Barito Pacific Tbk, BRPT | 1,690 IDR | 1,628 IDR | -4% |
| LG Chem, Ltd 051910 | 260,500 KRW | 587,755 KRW | +126% |
| Formosa Chemicals & Fibre Corporation 1326 | 66.10 TWD | 6.79 TWD | -90% |
| PTT Global Chemical Public Company PTTGC | 35.50 THB | 18.21 THB | -49% |
| 542812 542812 | ₹4,369 | ₹791.05 | -82% |
| Indorama Ventures Public Company IVL | 24.50 THB | 17.95 THB | -27% |
| Navin Fluorine International Limited NAVINFLUOR | ₹8,650 | ₹2,146 | -75% |
Compare Zhejiang Huakang Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Basic Materials stocks →
Frequently asked questions
Is Zhejiang Huakang Pharmaceutical Co (605077) overvalued or undervalued?
What is the fair value of 605077?
What is the quality score of 605077?
What is the revenue of Zhejiang Huakang Pharmaceutical Co (605077)?
What is the net profit margin of 605077?
Does Zhejiang Huakang Pharmaceutical Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Zhejiang Huakang Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.